GSK shingles vaccine shows benefits across all age groups

LONDON, April 28 (Reuters) - An experimental shingles vaccine from GlaxoSmithKline is effective across all age groups, researchers said on Tuesday, boosting the prospects of a key product in the British drugmaker's development pipeline.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.